Example: Heart Attack

Clinical Trials on Muscle Neoplasms

Total 745 results

NCT03924856

Recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Conditions: Urinary Bladder Cancer, Muscle-invasive
NCT03924895

Recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Conditions: Urinary Bladder Cancer, Muscle-invasive
NCT02380651

Unknown status

Functional Outcomes and HRQoL in Upper-extremity Sarcoma Patients After Limb Salvage

Conditions: Cancer of Muscle
NCT02287311

Recruiting

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

Conditions: Hodgkin Disease; Non-Hodgkin Lymphoma; Severe Chronic Active Epstein Barr Virus; T/NK-lymphoproliferative Disease; Nasopharyngeal Carcinoma; Smooth Muscle Tumor
NCT01707862

Completed

Surgery for Intravenous Leiomyomatosis

Conditions: Leiomyomatosis
NCT03773666

Recruiting

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Conditions: Muscle Invasive Bladder Cancer
NCT03832673

Unknown status

Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study

Conditions: Muscle-invasive Bladder Cancer
NCT04053101

Active, not recruiting

Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer

Conditions: Muscle Invasive Bladder Cancer
NCT02546661

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Conditions: Muscle Invasive Bladder Cancer
NCT03294304

Active, not recruiting

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Conditions: Muscle Invasive Bladder Cancer
NCT04101812

Recruiting

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Conditions: Muscle Invasive Bladder Cancer
NCT02716896

Terminated

Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer

Conditions: Muscle Invasive Bladder Cancer
NCT04660344

Not yet recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Conditions: Muscle-invasive Bladder Cancer
NCT04700124

Not yet recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

Conditions: Muscle Invasive Bladder Cancer
NCT03674424

Recruiting

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Conditions: Non-metastatic Muscle Invasive Bladder Cancer
NCT02621151

Active, not recruiting

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Conditions: Muscle-invasive Urothelial Cancer of the Bladder
NCT03234153

Terminated

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Conditions: Muscle-invasive Bladder Cancer
NCT03747419

Recruiting

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Conditions: Bladder Cancer; Muscle Invasive Bladder Cancer
NCT01031420

Completed

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Conditions: Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts
NCT04209114

Recruiting

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.

Conditions: Bladder Cancer; Bladder Tumor; Muscle-Invasive Bladder Cancer
NCT03551990

Recruiting

Influence of Motor Proteins on Muscle Atrophy in Cancer Patients

Conditions: Cancer; Muscle Atrophy
NCT04430036

Recruiting

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Conditions: Urinary Bladder Neoplasms
NCT02662062

Recruiting

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Conditions: Bladder Cancer
NCT04686149

Not yet recruiting

a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients

Conditions: Muscle-Invasive Bladder Carcinoma
NCT04144270

Recruiting

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Conditions: Urinary Bladder Neoplasm